BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barnieh FM, Loadman PM, Falconer RA. Progress towards a clinically-successful ATR inhibitor for cancer therapy. Current Research in Pharmacology and Drug Discovery 2021;2:100017. [DOI: 10.1016/j.crphar.2021.100017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Barnieh FM, Ribeiro Morais G, Garland H, Loadman PM, Falconer RA. Targeted delivery of a colchicine analogue provides synergy with ATR inhibition in cancer cells. Biochemical Pharmacology 2022. [DOI: 10.1016/j.bcp.2022.115095] [Reference Citation Analysis]
2 Karukonda P, Odhiambo D, Mowery YM. Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma. Mol Carcinog 2021. [PMID: 34964992 DOI: 10.1002/mc.23384] [Reference Citation Analysis]
3 Kiesel BF, Guo J, Parise RA, Venkataramanan R, Clump DA, Bakkenist CJ, Beumer JH. Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice. Cancer Chemother Pharmacol. [DOI: 10.1007/s00280-021-04388-x] [Reference Citation Analysis]
4 Parsels LA, Zhang Q, Karnak D, Parsels JD, Lam K, Willers H, Green MD, Rehemtulla A, Lawrence TS, Morgan MA. Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02621-3. [PMID: 34348175 DOI: 10.1016/j.ijrobp.2021.07.1708] [Reference Citation Analysis]
5 Maresca L, Stecca B, Carrassa L. Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. Cells 2022;11:1466. [DOI: 10.3390/cells11091466] [Reference Citation Analysis]
6 Smith G, Alholm Z, Coleman RL, Monk BJ. DNA Damage Repair Inhibitors-Combination Therapies. Cancer J 2021;27:501-5. [PMID: 34904813 DOI: 10.1097/PPO.0000000000000561] [Reference Citation Analysis]
7 Hu S, Hui Z, Duan J, Garrido C, Xie T, Ye XY. Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present. Expert Opin Ther Pat 2022. [PMID: 35001778 DOI: 10.1080/13543776.2022.2027911] [Reference Citation Analysis]
8 Schnöller LE, Albrecht V, Brix N, Nieto AE, Fleischmann DF, Niyazi M, Hess J, Belka C, Unger K, Lauber K, Orth M. Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy. Radiat Oncol 2022;17:79. [PMID: 35440003 DOI: 10.1186/s13014-022-02052-z] [Reference Citation Analysis]
9 Gönül Geyik Ö, Anichini G, Ulukaya E, Marra F, Raggi C. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells 2022;11:1463. [DOI: 10.3390/cells11091463] [Reference Citation Analysis]
10 Han Y, Wen P, Li J, Kataoka K. Targeted nanomedicine in cisplatin-based cancer therapeutics. J Control Release 2022;345:709-20. [PMID: 35367476 DOI: 10.1016/j.jconrel.2022.03.049] [Reference Citation Analysis]